Ancestral Genetic Homogeneity in Preclinical Models May Shape Outcome Differences in Pediatric Brain Cancer.

Preclinical models of pediatric brain tumors lack ancestral diversity, potentially skewing treatment responses and perpetuating health disparities in minority populations.

• Why it matters: Understanding how genetic ancestry influences tumor biology and therapy outcomes is crucial to addressing survival gaps and ensuring equitable treatment for all children with brain cancer.
• What they did: The review examined the role of genetic ancestry in pediatric brain tumor biology and treatment, analyzing population-linked genetic differences and the ancestral composition of cell line models, revealing overrepresentation of European and Asian ancestries.
• The result: Findings highlight that current models do not reflect ancestral heterogeneity, limiting clinical translation and underscoring the need to incorporate diverse genetic backgrounds to improve therapeutic development and reduce disparities.